Diabetes Journal Club Carina Signori 1/19/2012

Slides:



Advertisements
Similar presentations
Abstract Objective: Intensive insulin management (IIM) improves glycemic control, and lowers the risks of long-term microvascular complications. In children,
Advertisements

Diabetes in Young Women Francine R. Kaufman, M.D. Professor of Pediatrics The Keck School of Medicine of USC Head, Center for Diabetes and Endocrinology.
1 Type 1 Diabetes Mellitus Treatment. 2 Goals of T1DM Management Utilize intensive therapy aimed at near-normal BG and A1C levels Prevent diabetic ketoacidosis.
Diabetes Care Summary of Revisions for the 2014 Clinical Practice Recommendations Copied from:
Task Force on Diabetes and CVD (ESC and EASD) European Heart Journal 2007;28:
1 Prediabetes Comorbidities and Complications. 2 Common Comorbidities of Prediabetes Obesity CVD Dyslipidemia Hypertension Renal failure Cancer Sleep.
Improved Glucose Control With Weight Loss, Lower Insulin Doses, and No Increased Hypoglycemia With Empagliflozin Added to Titrated Multiple Daily Injections.
Diabetes Mellitus Type 2
Pramlintide Advisory Committee July 26, 2001 Symlin ® Amylin Pharmaceuticals New Drug Application (21-332) Advisory Committee Meeting Bethesda, Maryland.
Facts and Fiction about Type 2 Diabetes Michael L. Parchman, MD Department of Family & Community Medicine September 2004.
Canadian Diabetes Association 2013 Clinical Practice Guidelines Targets for Glycemic Control Chapter 8 S. Ali Imran, Rémi Rabasa-Lhoret, Stuart Ross.
Diabetes Mellitus Ibrahim Sales, Pharm.D. Assistant Professor of Clinical Pharmacy King Saud University
INSULIN THERAPY IN TYPE 1 DIABETES
Individualizing Targets and Tactics for High- Risk Patients With Type 2 Diabetes Practical lessons from ACCORD and other cardiovascular trials Featured.
Summary of Revisions for the 2013 Clinical Practice Recommendations Copied from:
Rapid Rise in Hypertension and Nephropathy in Youth With Type 2 Diabetes The TODAY clinical trial Featured Article: TODAY Study Group* Diabetes Care Volume.
Diabetes: The Modern Epidemic Roy Buchinsky, MD Director of Wellness.
Diabetic Nephropathy in the Adolescent Age Group Henry Rodriguez, M.D. Associate Professor of Pediatrics Indiana University School of Medicine Director,
Diabetes Control and Complications Trial (DCCT) Results indicate that most youth with T1DM should be treated intensively in order to reduce the risk of.
Diabetes: What’s New? What’s Next? Robert P. Hoffman, M.D. Grand Rounds June 1, 2007.
Use of The FreeStyle Navigator TM Continuous Glucose Monitoring System in Children on Glargine- based Multiple Daily Injection Therapy Stuart Weinzimer.
Effect of Hypertension and Dyslipidemia on glycemic control among Type 2 Diabetes patients in Thailand Dr. Mya Thandar DrPH Batch 5 1.
Clinical Practice Glycemic Management of Type 2 Diabetes Mellitus Faramarz Ismail-Beigi, M.D., Ph.D. Dr.kalantar N Engl J Med Volume 366(14):
Carina Signori, DO Journal Club August 2010 Macdonald, M. et al. Diabetes Care; Jun 2010; 33,
Carina Signori, D.O., M.P.H. Penn State Hershey Medical Center Ceriello, Antonio. Diabetes Care August 2010;33,8.
Primary Care Prescribing for Type 2 Diabetes Dr. David Jenkins Worcestershire Royal Hospital.
Getting the Message Across: Teaching Diabetes Management Through Text Messages Scott Bragg, PharmD Kristen Hood Watson, MD Medical University of South.
Circulation. 2014;129: Association Between Plasma Triglycerides and High-Density Lipoprotein Cholesterol and Microvascular Kidney Disease and Retinopathy.
OPD follow up 1. General P/E Blood pressure Sites of insulin injection Deep tendon reflex 2.
R1. 이정미 / prof. 이상열. INTRODUCTION Type 2 diabetes is a major risk factor for cardiovascular disease The presence of both type 2 diabetes and.
Statins The AURORA Trial Reference Fellstrom BC. Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N Engl J Med. 2009;360. A.
Diabetes Clinical Audit- July/Aug 2014
HbA1c before Ramadan (%)
Diabetes Journal Club Carina Signori Endocrinology Fellow
Safety and efficacy of insulin guideline for controlling perioperative hyperglycemia Marwa Amer PharmD Candidate1, Mark Shelly MD2, Dianne Lee PharmD Candidate1,
Insulin Delivery Systems Atlanta Diabetes Associates
Metabolic Changes in Diabetes Mellitus
Treatment algorithm for management of type 2 diabetes mellitus
«Effects of Multidisciplinary and structured education programme on glycaemic control during transition of young adults with type 1 diabetes» Da Porto.
Key publication slides
Diabetes and Obesity Journal Club Carina Signori, D.O., M.P.H.
Metabolic Changes in Diabetes Mellitus
US Medical Professionals’ Knowledge of the Diabetes Control and Complications Trial Austin Bach, DO, MPH, Mohamad ElChurafa, BS, Daniel Solano, DO, Marcos.
Copyright © 2017 American Academy of Pediatrics.
Metabolic Changes in Diabetes Mellitus
The CANUSA Trial Reference
Jagadesh M ,SURYA NARAYANA J, JAYAPRAKASH, NRRAU
Diabetes Health Status Report
Diabetes and Risk of CV Outcomes
Macrovascular Complications Microvascular Complications
366 میلیون نفر در جهان مبتلا به دیابت هستند.
Diabetes: Microvascular Complications and Foot Care
The following slides highlight an educational report based on a Satellite Symposium presentation at the 2008 Canadian Cardiovascular Congress in Toronto.
Diabetes Journal Club January 19, 2012 Margaux Añel-Tiangco, MD
Incidence of CV Events in Subjects With T2D vs the Nondiabetic CAD Population
Accepted 2 June Ryan Chen
Faster-Acting Insulins
Chapter 1: CKD in the General Population
Patients With T2D Presenting With Glycosuria: Examining the SGLT2 MOA
DiRECT (Diabetes Remission Clinical Trial)
The Cardiologist's Mindset in the Management of Diabetes and Coronary Artery Disease: Today and Tomorrow.
Diabetes Journal Club March 17, 2011
Incidence of CV Events in Subjects With T2D vs the Nondiabetic CAD Population
CV Risk Reduction with Diabetes Drugs -- Should Cardiologists or Diabetologists Take the Lead?
Pharmacotherapy for Diabetic Coronary Disease:
Journal of Indian College of Cardiology
Patients With T2D Presenting With Glycosuria: Examining the SGLT2 MOA
Type 1 Diabetes: Expanding Options for Adjunctive Oral Therapy With SGLT Inhibitors.
PowerPoint 16:9 Screen Ratio Template *
Hyperglycemic Targets & Hypoglycemia
Presentation transcript:

Diabetes Journal Club Carina Signori 1/19/2012 -- Diabetes Journal Club Carina Signori 1/19/2012

Type 1 DM in Adolescents The Diabetes Control and Complications Trial (DCCT)-- 1994 Prevalence of retinopathy in adolescents 41-46%. Microalbuminuria ranged between 4-20%. Intensive glucose management was associated with reduced microvascular complications in adults and adolescents. Post DCCT Intensive glucose management was recommended but difficult to obtain in young people. Yet, the authors reported a reduction in retinopathy and borderline elevation of albumin excretion rate (AER)/albumin-to-creatinine ratio (ACR). Microabluminuria declined then plateaued.

Type I DM in Children The association between intensive treatment regimens (continuous SQ infusion or MDI) and improved glycemic control has not been clearly established. No evidence showing reduced risk of complications in children treated with CSQI or MDI versus 1-2 injections/day.

Aim Examine trends in the prevalence of microvascular complications from 1990-2009. Association of time period and complications. Association of risk factors, socioeconmic factors and treatment regimens.

Methods Subjects: Inclusion criteria: Complications assessment 1604 patients with type 1 DM evaluated between1990- 2009. Inclusion criteria: Age 12-20 years Diabetes for ≥5 years. Complications assessment Retinopathy – eye exam Microalbuminuria: ↑AER/ACR,↑ microalbuminuria Peripheral nerve function– thermal and vibration thresthold testing. Glycemic control: GHb colorimetrically (before 2/1994) then hemoglobin A1C.

Results

No change

Conclusions This study looked at the microvascular complications in the adolescent population with type 1 DM. Retinopathy prevalence decreased in parallel with HbA1C. Microalbuminuria and peripheral nerve abnormalities plateaued. Severe hypoglycemia remained unchanged. This suggests that lower glycemic targets and intensive insulin may be beneficial in children and adolescents.